Longitudinal Study on Low-Dose Aspirin versus Placebo Administration in Silent Brain Infarcts: The Silence Study

Table 4

Number and rates of secondary endpoints, tolerability and drop out occurrences during the trial.

	ASA n=36	controls n=47
	n (%)	n (%)
Primary endpoint	2 (5.6)	9 (19.1)
Other cardiovascular events	2 (5.6)	1 (2.1)
Adverse events	2 (5.6)	2 (4.2)
Switch ASA	-	2 (4.2)
Lost to follow-up	9 (25.0)	9 (19.1)
Mortality	-	1 (2.1)
Low compliance	2 (5.6)	-
Withdraws consent	4 (11.1)	-
Completed follow-up	15 (41.7)	23 (48.9)